IP Library Granted Patent US 12,409,339
Granted Patent B2
US 12,409,339 · App. 18/020,847 · Granted Sep 9, 2025

Internal ultraviolet therapy

Inventors: Ali Rezaie (Beverly Hills, CA); Mark Pimentel (Los Angeles, CA); Gil Y. Melmed (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center
A61N5/0624A61N5/0601A61N2005/002A61N2005/0651A61N2005/0661
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,339
App. No.
18/020,847
Granted
Sep 9, 2025
Kind
B2
Abstract

Methods and systems one or more for performing intra-luminal ultraviolet therapy for treating and/or ameliorating a gastrointestinal tract inflammation and/or infection are provided. In one example, a light delivery catheter may include a light emitting portion and non-illuminating portion, wherein the light emitting portion may include one or more UV transparent balloons. In some examples, the UV light source is configured to emit narrow-band light having wavelengths in a range between 335 nm and 349 nm.

Claims (45)

1. A light delivery device for performing intra-luminal light therapy, the device comprising:

a delivery tube comprising a light emitting portion, the light emitting portion including a plurality of light sources configured to emit narrow-band light at wavelengths in an ultraviolet A (UV-A) range between 335 nm and 349 nm; and

a plurality of distendable balloons connected to the delivery tube at the light emitting portion, each of the plurality of distendable balloons in fluid communication with a respective inflation port;

wherein each of the plurality of distendable balloons is composed of an ultraviolet (UV) transparent material.

2. The light delivery device of claim 1 , wherein each of the plurality of distendable balloons are configured to increase irradiance and/or irradiance distribution of light emitted from the plurality of light sources and delivered to a corresponding intra-luminal treatment site.

3. The light delivery device of claim 1 , wherein the plurality of distendable balloons are arranged serially along a length of the light emitting portion; and wherein a separation between any two of the plurality of distendable balloons is adjustable.

4. The light delivery device of claim 3 , wherein the light emitting portion comprises one or more segments that are not connected to the plurality of distendable balloons; and wherein the one or more segments include one or more light sources of the plurality of light sources.

5. The light delivery device of claim 1 , wherein the plurality of light sources are light emitting diodes (LEDs) electrically connected to a power source; and wherein the plurality of light sources are configured to emit light outwardly from the delivery device.

6. The light delivery device of claim 1 , wherein the plurality of light sources are positioned on a cooling tube within the delivery device, the cooling tube configured to receive cooling air from a cooling system including a medical-grade compressor and a chiller.

7. The light delivery device of claim 1 , wherein the plurality of light sources are configured to emit peak wavelengths the UV-A range between 338 nm and 346 nm.

8. The light delivery device of claim 1 , further comprising a balloon control unit configured for inflating and/or deflating each of the plurality of distendable balloons via the respective balloon inflation port.

9. The light delivery device of claim 1 , further comprising a guide wire channel within the delivery tube and extending throughout a length of the delivery tube, the guide wire channel configured for passing the delivery device over a guide wire positioned within a lumen of a patient.

10. The light delivery device of claim 1 , wherein the UV-transparent material is polyether block amide (PEBA) or Cyclic olefin copolymer (COC) or silicone.

11. The light delivery device of claim 1 , wherein the plurality of distendable balloons includes at least three balloons.

12. A method for performing intra-luminal ultraviolet (UV) therapy comprising:

providing a UV light delivery device comprising:

a delivery tube comprising a plurality of light emitting segments, each of the plurality of light emitting segments including a plurality of light emitting diodes (LEDs) configured to emit narrow-band light having wavelengths in an ultraviolet A (UV-A) range between 338 nm and 346 nm; and

a plurality of distendable balloons, each of the plurality of distendable balloons coupled to one of the plurality of light segments and each of the plurality of distendable balloons fluidly coupled to a respective inflation port coupled to a balloon control unit;

wherein the plurality of distendable balloons are composed of UV transmitting materials;

positioning the delivery tube within a lumen of a gastrointestinal (GI) tract of a patient with each the plurality of distendable balloons in a deflated condition;

selectively inflating the plurality of distendable balloons via the balloon control unit;

and energizing the plurality of LEDs for a threshold duration and a threshold intensity based on one or more of type and an overall severity of a disorder of the GI tract.

13. The method of claim 12 , wherein positioning the delivery tube within the lumen comprises aligning one or more of the plurality of distendable balloons with one or more diseased areas within the lumen.

14. The method of claim 13 , wherein selectively inflating the plurality of distendable balloons includes inflating the one or more distendable balloons that align with the one or more diseased areas while maintaining a remaining number of balloons that align with normal healthy tissues in a deflated condition.

15. The method of claim 13 , wherein selectively inflating the one or more distendable balloons that align with the one or more diseased areas includes pressurizing the one or more distendable balloons to a threshold pressure at which the one or more distendable balloons contact an epithelial layer of the lumen.

16. The method of claim 15 , wherein the threshold pressure is based on a diameter of the lumen.

17. The method of claim 12 , further comprising: during one condition, when one or more target areas have different severities of infection and/or inflammation, for a given light emitting segment, adjusting an amount of light intensity based on a local severity of infection and/or inflammation at the one or more target areas.

18. The method of claim 12 , wherein the delivery tube includes a coolant tube configured to receive cooling air from a compressor; and further comprising monitoring a temperature of the delivery tube via a thermistor, and adjusting a coolant flow rate through the coolant tube based on the temperature.

19. The method of claim 12 , wherein the delivery tube is configured as an endoscope comprising one or more cameras for visualizing the lumen.

20. The method of claim 12 , wherein the UV transmitting material includes polyether block amide (PEBA) or Cyclic olefin copolymer (COC) or silicone.

21. The method of claim 12 , wherein positioning the delivery tube within the lumen comprises passing the delivery tribe over a guide wire positioned within the lumen, the guide wire positioned within the lumen using an endoscope.

22. A method of treating, ameliorating, and/or preventing a gastrointestinal disorder in a patient, the method comprising:

providing a delivery tube; the delivery tube comprising a light emitting portion including a set of light emitting diodes (LEDs) and at least one distendable balloon coupled to the light emitting portion;

navigating the delivery tube into a lumen of a patient's gastrointestinal tract, positioning the at least one distendable balloon to align with a target area in the lumen requiring ultraviolet (UV) light treatment,

inflating the at least one distendable balloon via a balloon inflation port fluidly coupled to the at least one distendable balloon; and

energizing the set of LEDs connected to the delivery tube and positioned inside the at least one distendable balloon for a duration and an intensity sufficient to treat the gastrointestinal disorder;

wherein the set of LEDs are configured to emit narrow-band light having wavelengths in a UV-range between 335 nm and 349 nm.

23. The method of claim 22 , wherein the at least one distendable balloon is composed of an UV transmitting material, the UV transmitting material having UV transmittance in a range between eight percent and one hundred percent.

24. The method of claim 22 , wherein the at least one distendable balloon is constructed using a material including polyether block amide (PEBA) or Cyclic olefin copolymer (COC) or silicone.

25. The method of claim 22 , wherein inflating the at least one distendable balloon includes pressurizing the at least one distendable balloon to a threshold pressure at which the at least one distendable balloons is in direct contact with a desired surface area of an epithelial layer of the lumen.

26. The method of claim 22 , wherein the threshold pressure is based on a diameter of the lumen.

27. The method of claim 22 , wherein the intensity comprises at least 1,100 microwatt/cm 2 , 1,500 microwatt/cm 2 , 2,000 microwatt/cm 2 , 2,100 microwatt/cm 2 , 2,200 microwatt/cm 2 , 2,300 microwatt/cm 2 , 2,400 microwatt/cm 2 , 2,500 microwatt/cm 2 , 2,600 microwatt/cm 2 , 2,700 microwatt/cm, 2,800 microwatt/cm 2 , 2,900 microwatt/cm 2 , 3,000 microwatt/cm 2 , or 4 milliwatt/cm 2 .

28. The method of claim 22 , wherein the gastrointestinal disorder is a form of inflammatory bowel disease.

29. The method of claim 28 , wherein the form of inflammatory bowel disease comprises ulcerative colitis and/or Crohn's disease.

30. The method of claim 22 , wherein the gastrointestinal disorder comprises at least one of: ulcerative colitis, Crohn's disease, pouchitis, proctitis, fistula, inflammatory strictures, microscopic colitis, infections diarrhea, refractory Helicobater pylori , MALT lymphoma, colonic inertia, tropical sprue, celiac disease, small intestinal bacterial overgrowth, typhlitis, post-bone marrow transplant infections, pseudopolyps, radiation enteritis, refractory Clostridium difficile , gastrointestinal cancers, hepatobiliary infections, and/or inflammation and cancers of the mucosa and submucosa.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2023
From: REZAIE, ALI; PIMENTEL, MARK; MELMED, GIL Y.
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 062660/0971 →
Continuity (2)
Provisional Application 63065167 · Aug 13, 2020
Related Publication 20230302292A1 · Sep 28, 2023
References Cited (136)
US 5053033A · Clarke · 1991 [cited by applicant]
US 5573531A · Gregory · 1996 [cited by applicant]
US 5855203A · Matter · 1999 [cited by applicant]
US 6316872B1 · Ge et al. · 2001 [cited by applicant]
US 6890346B2 · Ganz · 2005 [cited by examiner]
US 7311722B2 · Larsen · 2007 [cited by applicant]
US 7409954B2 · Dobkine et al. · 2008 [cited by applicant]
US 9014789B2 · Mercader · 2015 [cited by examiner]
US 9023092B2 · Natale et al. · 2015 [cited by applicant]
US 9820798B2 · Schwartz · 2017 [cited by applicant]
US 10004918B2 · Klang · 2018 [cited by applicant]
US 10357661B2 · Hellstrom et al. · 2019 [cited by applicant]
US 10842567B2 · Grace et al. · 2020 [cited by applicant]
US 11179575B2 · Rezaie et al. · 2021 [cited by applicant]
US 11318325B2 · Rezaie et al. · 2022 [cited by applicant]
US 11571586B2 · Xu · 2023 [cited by examiner]
US 11992699B2 · Rezaie · 2024 [cited by examiner]
US 20020120358A1 · Lalonde · 2002 [cited by applicant]
US 20030191459A1 · Ganz · 2003 [cited by examiner]
US 20040232359A1 · Fiset · 2004 [cited by applicant]
US 20050070759A1 · Armstrong · 2005 [cited by applicant]
US 20050075703A1 · Larsen · 2005 [cited by applicant]
US 20050106710A1 · Friedman et al. · 2005 [cited by applicant]
US 20050107853A1 · Krespi et al. · 2005 [cited by applicant]
US 20050177208A1 · Irwin · 2005 [cited by applicant]
US 20060047329A1 · Krespi et al. · 2006 [cited by applicant]
US 20060069314A1 · Farr · 2006 [cited by applicant]
US 20060127531A1 · Jobe · 2006 [cited by applicant]
US 20060130846A1 · Rife · 2006 [cited by applicant]
US 20060167531A1 · Gertner et al. · 2006 [cited by applicant]
US 20060183987A1 · Murray · 2006 [cited by applicant]
US 20060217787A1 · Olson · 2006 [cited by applicant]
US 20070135874A1 · Bala · 2007 [cited by applicant]
US 20080033519A1 · Burwell · 2008 [cited by applicant]
US 20080073565A1 · Jeon · 2008 [cited by applicant]
US 20080159908A1 · Redmond · 2008 [cited by applicant]
US 20080194973A1 · Imam · 2008 [cited by applicant]
US 20080257355A1 · Rao et al. · 2008 [cited by applicant]
US 20090179547A1 · Auday · 2009 [cited by applicant]
US 20090216177A1 · Akiyama et al. · 2009 [cited by applicant]
US 20090287137A1 · Crowley · 2009 [cited by applicant]
US 20100220472A1 · Dahm · 2010 [cited by applicant]
US 20100241198A1 · Klepper · 2010 [cited by applicant]
US 20110084275A1 · Yamamuro et al. · 2011 [cited by applicant]
US 20110226966A1 · Takahashi et al. · 2011 [cited by applicant]
US 20110313299A1 · Brennan, III · 2011 [cited by examiner]
US 20120004710A1 · Kerber · 2012 [cited by applicant]
US 20120321509A1 · Bak · 2012 [cited by examiner]
US 20130102862A1 · Mercader · 2013 [cited by examiner]
US 20130104884A1 · Vazales · 2013 [cited by applicant]
US 20130178788A1 · Jaquins-Gerstl · 2013 [cited by applicant]
US 20130261368A1 · Schwartz · 2013 [cited by applicant]
US 20130274549A1 · Natale et al. · 2013 [cited by applicant]
US 20140150782A1 · Vazales · 2014 [cited by applicant]
US 20140235942A1 · Hellstrom et al. · 2014 [cited by applicant]
US 20150209457A1 · Bonutti et al. · 2015 [cited by applicant]
US 20150359595A1 · Ben Oren · 2015 [cited by examiner]
US 20160008624A1 · Grossman · 2016 [cited by applicant]
US 20160038621A1 · Victor et al. · 2016 [cited by applicant]
US 20160114185A1 · Mankin · 2016 [cited by applicant]
US 20160128767A1 · Azamian · 2016 [cited by applicant]
US 20160151639A1 · Scharf et al. · 2016 [cited by applicant]
US 20170265942A1 · Grace et al. · 2017 [cited by applicant]
US 20170281966A1 · Basiony · 2017 [cited by applicant]
US 20190168023A1 · Eltorai · 2019 [cited by applicant]
US 20190175938A1 · Rezaie et al. · 2019 [cited by applicant]
US 20200030473A1 · Sugimoto · 2020 [cited by examiner]
US 20200046835A1 · Kamaev et al. · 2020 [cited by applicant]
US 20200121943A1 · Anderson · 2020 [cited by examiner]
US 20200147409A1 · Basiony · 2020 [cited by applicant]
US 20200346032A1 · Rezaie et al. · 2020 [cited by applicant]
US 20210106844A1 · Rezaie et al. · 2021 [cited by applicant]
US 20210205632A1 · Xu · 2021 [cited by examiner]
US 20220040497A1 · Rezaie · 2022 [cited by applicant]
US 20230035292A1 · Rezaie et al. · 2023 [cited by applicant]
US 20230147752A1 · Rezaie et al. · 2023 [cited by applicant]
US 20240024697A1 · Rezaie et al. · 2024 [cited by applicant]
US 20240198131A1 · Pimentel et al. · 2024 [cited by applicant]
US 20240366960A1 · Rezaie et al. · 2024 [cited by applicant]
AU 2017273699A1 · 2018 [cited by applicant]
CA 2515304A1 · 2004 [cited by applicant]
CA 3024711A1 · 2017 [cited by applicant]
CN 1646191A · 2005 [cited by applicant]
CN 109414591A · 2019 [cited by applicant]
EP 3463570A1 · 2019 [cited by applicant]
EP 3893993 · 2021 [cited by applicant]
HK 40001485A · 2020 [cited by applicant]
IN 201827043869A · 2019 [cited by applicant]
JP 2000285854A · 2000 [cited by applicant]
JP 2007511286A · 2007 [cited by applicant]
JP 2007511279A · 2007 [cited by applicant]
JP 2008528188A · 2008 [cited by applicant]
JP 2009505365A · 2009 [cited by applicant]
JP 2011530327A · 2011 [cited by applicant]
JP 2014233712A · 2014 [cited by applicant]
JP 2015505678A1 · 2015 [cited by applicant]
JP 2019517305A · 2019 [cited by applicant]
KR 20190015357A · 2019 [cited by applicant]
MX 2018014694A · 2019 [cited by applicant]
NZ 748479A · 2021 [cited by applicant]
SG 11201810515T · 2018 [cited by applicant]
WO 2010029292A1 · 2010 [cited by applicant]
WO 2010058607A1 · 2010 [cited by applicant]
WO 2011083381A1 · 2011 [cited by applicant]
WO 2014022867A1 · 2014 [cited by applicant]
WO 2014165854A1 · 2014 [cited by applicant]
WO 2017210366A1 · 2017 [cited by applicant]
WO 2021076399A1 · 2021 [cited by applicant]
WO 2021189020A1 · 2021 [cited by applicant]
WO 2021202402A1 · 2021 [cited by applicant]
WO 2022036263A1 · 2022 [cited by applicant]
WO 2022235966A1 · 2022 [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/035316 dated Oct. 2, 2017,. [cited by applicant]
European Supplementary Search Report for EP17807445.6 dated Feb. 26, 2020, 14 pages. [cited by applicant]
Extended European Search Report or EP17807445.6 dated Jun. 25, 2020, 13 pages. [cited by applicant]
SR and WO for PCT/US20/054758 dated Jan. 11, 2021, 9 pages. [cited by applicant]
JP Notice of Reasons for Rejection for JP2018-562598 dated Nov, 2, 2020, 16 pages. [cited by applicant]
NZ Examination Report for App No. 748479 Oct. 14, 2020, 5 pages. [cited by applicant]
NZ Examination Report for App No. 748479 Mar. 24, 2021, 4 pages. [cited by applicant]
Hamamoto et al., New water disinfection system using UVA light-emitting diodes, Journal of Applied Microbiology, Aug. 30, 2007, vol. 103:6: 2291-2298. [cited by applicant]
Aihara, et al., Vegetable surface Sterilization system using UVA Light-Emitting Diodes, Journal of Medical Invesstigation, Sep. 27, 2014, vol. 61, pp. 285-290. [cited by applicant]
SG Written Opinion for 11201810515T dated Mar. 2, 2020, 4 pages. [cited by applicant]
SG Written Opinion for 11201810515T dated Jan. 20, 2021, 7 pages. [cited by applicant]
Wikipedia, Inverse-square law, 2021; https://en.wikipedia.org/wiki/inverse-square_law#Light_and_other_electromagnetic_radiation (Year: 2021). [cited by applicant]
Extended European Search Report for EP 20877251.7 dated Jan. 21, 2022, 6 pages. [cited by applicant]
ISR-WO for PCT/US2021/023354 dated Jun. 30, 2021, 9 pages. [cited by applicant]
European Centre for Disease Prevention and Control, Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2): increased transmission beyond China—fourth update, Feb. 14, 2020 [retrieved May 26, 2021], re… [cited by applicant]
Pekmezovic et al., Candida pathogens induce protective mitochondria-associated type I interferon signalling and a damage-driven response in vaginal epithelial cells, Nature Microbiology, 2021, pp. 643-657. [cited by applicant]
SR-WO for PCT/US2021/046011 dated Nov. 17, 2021, 10 pages. [cited by applicant]
JP Notice of Reasons for Rejection for JP2018-562598 dated Jul. 7, 2022, 5 pages. [cited by applicant]
PRP for PCT/US20/054758 dated Apr. 19, 2022, 9 pages. [cited by applicant]
European Search Report for EP21771541.6 dated Apr. 19, 2024, 7 pages. [cited by applicant]
SESR for 21856823.6 dated Apr. 20, 2024, 8 pages. [cited by applicant]
CA Exam Report for 3,172,543 dated Nov. 29, 2024, 4 pages. [cited by applicant]
Notice of Reasons for Rejection for JP 2023-509643 dated May 1, 2025, 15 pages (with translation). [cited by applicant]
IL Office Action for IL 263062, Mar. 26, 2025, 17 pages. [cited by applicant]